Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and Metastases.
brain cancer
brain metastasis
radionuclide therapy
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
01 Aug 2019
01 Aug 2019
Historique:
received:
18
06
2019
revised:
12
07
2019
accepted:
17
07
2019
entrez:
4
8
2019
pubmed:
4
8
2019
medline:
4
8
2019
Statut:
epublish
Résumé
Brain tumors are notoriously difficult to treat. The blood-brain barrier provides a sanctuary site where residual and metastatic cancer cells can evade most therapeutic modalities. The delicate nature of the brain further complicates the decision of eliminating as much tumorous tissue as possible while protecting healthy tissue. Despite recent advances in immunotherapy, radiotherapy and systemic treatments, prognosis of newly diagnosed patients remains dismal, and recurrence is still a universal problem. Several strategies are now under preclinical and clinical investigation to optimize delivery and maximize the cytotoxic potential of pharmaceuticals with regards to brain tumors. This review provides an overview of targeted radionuclide therapy approaches for the treatment of primary brain tumors and brain metastases, with an emphasis on biological targeting moieties that specifically target key biomarkers involved in cancer development.
Identifiants
pubmed: 31374991
pii: pharmaceutics11080376
doi: 10.3390/pharmaceutics11080376
pmc: PMC6723032
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Fonds Wetenschappelijk Onderzoek
ID : 1S27716N
Organisme : Wetenschappelijk Fonds Willy Gepts
ID : Not applicable
Déclaration de conflit d'intérêts
M.D., N.D. and T.L. are employees or consultants of Camel-IDS and holds ownership interest (including patents) in VHH radiotherapeutics, and they declare no conflict of interest. No potential conflicts of interest were disclosed by J.P.
Références
Clin Cancer Res. 1999 May;5(5):1025-33
pubmed: 10353735
Nucl Med Biol. 1999 May;26(4):405-11
pubmed: 10382844
Cancer Chemother Pharmacol. 2000;45(4):284-90
pubmed: 10755316
J Clin Oncol. 2000 Nov 15;18(22):3862-72
pubmed: 11078500
J Bone Miner Res. 2001 Aug;16(8):1486-95
pubmed: 11499871
J Clin Oncol. 2002 Mar 1;20(5):1389-97
pubmed: 11870184
Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):486-93
pubmed: 11914886
Semin Nucl Med. 2002 Apr;32(2):133-40
pubmed: 11965608
Tumour Biol. 2002 Mar-Apr;23(2):61-9
pubmed: 12065843
Blood. 2002 Aug 1;100(3):905-11
pubmed: 12130501
Cancer. 2002 May 15;94(10):2698-705
pubmed: 12173339
Int J Cancer. 2002 Nov 1;102(1):75-85
pubmed: 12353237
J Clin Oncol. 2002 Nov 1;20(21):4368-80
pubmed: 12409337
Acta Neuropathol. 2003 Jan;105(1):49-57
pubmed: 12471461
Am J Clin Oncol. 2002 Dec;25(6):541-6
pubmed: 12477994
Neuro Oncol. 2003 Apr;5(2):96-103
pubmed: 12672281
J Neuroimmunol. 1992 Jan;36(1):41-55
pubmed: 1370958
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):972-5
pubmed: 14967458
Curr Pharm Des. 2004;10(13):1537-49
pubmed: 15134574
Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1269-71
pubmed: 15275708
Q J Nucl Med Mol Imaging. 2004 Sep;48(3):220-8
pubmed: 15499296
J Neurosurg. 2004 Dec;101(6):1004-11
pubmed: 15597761
Semin Oncol. 2005 Feb;32(1 Suppl 1):S27-35
pubmed: 15786023
Neurosurgery. 2005 Jun;56(6):1243-52; discussion 1252-3
pubmed: 15918940
Cancer. 2005 Nov 1;104(9):1968-74
pubmed: 16177987
J Neurooncol. 2006 Mar;77(1):33-45
pubmed: 16200342
J Clin Oncol. 2006 Jan 1;24(1):115-22
pubmed: 16382120
Semin Nucl Med. 2006 Apr;36(2):147-56
pubmed: 16517236
Cancer Res. 2006 Mar 15;66(6):3294-302
pubmed: 16540683
Expert Opin Biol Ther. 2006 May;6(5):539-45
pubmed: 16610983
J Clin Oncol. 2006 May 20;24(15):2276-82
pubmed: 16710024
Neuro Oncol. 2006 Jul;8(3):234-43
pubmed: 16723631
Clin Cancer Res. 2006 Jun 15;12(12):3792-802
pubmed: 16778107
Clin Cancer Res. 2006 Jun 15;12(12):3843-50
pubmed: 16778112
Int J Cancer. 2007 Aug 15;121(4):901-7
pubmed: 17437269
J Nucl Med. 2008 Jan;49(1):30-8
pubmed: 18077533
Cancer Biol Ther. 2008 Mar;7(3):333-9
pubmed: 18094616
Neuro Oncol. 2008 Apr;10(2):182-9
pubmed: 18287339
Int J Nanomedicine. 2008;3(2):181-99
pubmed: 18686778
Blood. 2009 Mar 5;113(10):2265-74
pubmed: 19131554
Nucl Med Biol. 2009 Aug;36(6):659-69
pubmed: 19647172
J Nucl Med. 2010 Mar;51(3):397-400
pubmed: 20150267
Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1335-44
pubmed: 20157707
J Neurosurg. 2010 Aug;113(2):192-8
pubmed: 20345222
J Neurosurg. 2011 Mar;114(3):624-32
pubmed: 20964595
Cochrane Database Syst Rev. 2012 Apr 18;(4):CD003869
pubmed: 22513917
Future Oncol. 2012 Jun;8(6):659-69
pubmed: 22764763
Continuum (Minneap Minn). 2012 Apr;18(2):295-311
pubmed: 22810128
Sci Transl Med. 2013 Apr 10;5(180):180ra48
pubmed: 23576814
Expert Opin Drug Deliv. 2013 Jul;10(7):907-26
pubmed: 23751126
FEBS J. 2013 Nov;280(21):5350-70
pubmed: 23777544
APMIS. 2014 Jun;122(6):482-9
pubmed: 24304465
Cancer Immunol Res. 2013 Aug;1(2):134-43
pubmed: 24777501
Neuro Oncol. 2014 Jul;16(7):896-913
pubmed: 24842956
Trials. 2014 May 10;15:165
pubmed: 24884731
Cancer Treat Rev. 2014 Sep;40(8):951-9
pubmed: 24909312
Nucl Med Commun. 2014 Dec;35(12):1284-90
pubmed: 25192189
Clin Nucl Med. 2015 Apr;40(4):328-9
pubmed: 25674861
Biomed Res Int. 2015;2015:320941
pubmed: 25866775
J Nucl Med. 2016 Jan;57(1):27-33
pubmed: 26449837
Semin Nucl Med. 2016 May;46(3):243-9
pubmed: 27067505
J Nucl Med. 2016 Oct;57(10):1576-1582
pubmed: 27127217
Expert Opin Biol Ther. 2016 Aug;16(8):1035-47
pubmed: 27145158
Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45
pubmed: 27223671
J Nucl Med. 2016 Nov;57(11):1771-1777
pubmed: 27261519
Curr Neuropharmacol. 2017;15(1):116-128
pubmed: 27306036
Adv Drug Deliv Rev. 2017 Jan 15;109:15-25
pubmed: 27637454
Sci Transl Med. 2016 Oct 26;8(362):362ps17
pubmed: 27797957
Cancer. 2017 Mar 1;123(5):734-750
pubmed: 27875627
Curr Oncol Rep. 2017 Feb;19(2):9
pubmed: 28220446
Indian J Nucl Med. 2017 Jan-Mar;32(1):13-15
pubmed: 28242977
J Nucl Med. 2017 Oct;58(10):1624-1631
pubmed: 28408529
Cell Oncol (Dordr). 2017 Jun;40(3):199-208
pubmed: 28534212
Clin Nucl Med. 2017 Sep;42(9):704-706
pubmed: 28719450
Clin Cancer Res. 2017 Nov 1;23(21):6616-6628
pubmed: 28751451
Front Immunol. 2017 Sep 25;8:1181
pubmed: 28993773
Biomed Phys Eng Express. 2017 Jun;3(3):
pubmed: 29081990
Neuro Oncol. 2017 Nov 6;19(suppl_5):v1-v88
pubmed: 29117289
Theranostics. 2018 Jan 1;8(1):292-303
pubmed: 29290808
Oncogene. 2018 Mar;37(12):1561-1575
pubmed: 29321659
J Nucl Med. 2018 May;59(5):795-802
pubmed: 29326358
Clin Cancer Res. 2018 Sep 1;24(17):4175-4186
pubmed: 29437767
Clin Cancer Res. 2018 Apr 15;24(8):1795-1804
pubmed: 29437794
Mol Cancer. 2018 Feb 19;17(1):38
pubmed: 29455650
J Neurooncol. 2018 Jul;138(3):581-589
pubmed: 29524126
J Nucl Med. 2018 Aug;59(8):1225-1233
pubmed: 29572254
Iran J Pathol. 2018 Winter;13(1):45-53
pubmed: 29731795
Theranostics. 2018 Aug 07;8(16):4462-4476
pubmed: 30214632
Front Pharmacol. 2018 Sep 13;9:879
pubmed: 30271342
Nat Med. 2019 Jan;25(1):111-118
pubmed: 30478424
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):614-622
pubmed: 30498897
Cancer Biother Radiopharm. 2019 Aug;34(6):413-416
pubmed: 30844298
Mol Cancer Ther. 2019 Jun;18(6):1092-1103
pubmed: 30962321
Clin Nucl Med. 2019 Jun;44(6):e382-e384
pubmed: 30985411
Cancer Res. 1995 Dec 1;55(23 Suppl):5952s-5956s
pubmed: 7493376
Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):427-31
pubmed: 8005794
Int J Cancer. 1994 Jan 2;56(1):72-7
pubmed: 8262681
Cancer Treat Rev. 1997 Jan;23(1):35-61
pubmed: 9189180
Neurosurgery. 1998 May;42(5):1083-99; discussion 1099-100
pubmed: 9588554